Compare Davita Inc (DVA) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Spotify Technology — how do they compare? Davita Inc trades at $230.26 (market cap $14.92B), while Spotify Technology trades at $480.69 (market cap $98.92B). The key difference: Spotify Technology is far larger — about 6.6× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| DVA | SPOT | |
|---|---|---|
Market Cap | $14.92B | $98.92B |
Sector | Health | Media |
52-Week High | $235.71 | $738.53 |
52-Week Low | $103.87 | $412.75 |
Enterprise Value | $27.47B | $89.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Spotify (SPOT) trades at $479.84, showing minimal daily movement (+0.01%) amid neutral technical signals. The company demonstrates strong fundamental momentum with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability turnaround from losses to $2.2B net income. Recent earnings beats and AI integration initiatives highlight operational strength, though technical indicators show mixed signals with bearish moving averages and neutral oscillators.
Spotify presents a compelling growth story with accelerating profitability and analyst optimism (61.5% buy ratings), though faces execution risks in competitive streaming markets. The stock trades at a premium valuation (P/E 32.7) but offers 28% upside to consensus target of $617. Key risks include market saturation and royalty cost pressures, while AI innovation provides growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
